Mpox: Understanding the Fatality Rate and Treatment Options of the Virus

Mpox, formerly known as monkeypox, is currently in the midst of an outbreak in the Democratic Republic of Congo (DRC) and neighboring countries, with the surge in cases being blamed in part on a new variant that is thought to be more deadly than the variant of the Mpox virus that caused a global outbreak in 2022. But there are treatments that may help.

How deadly is MPOX?

Studies have shown that the mortality rate among people infected with the currently circulating lineage I variant of MPOX is approximately 1-2%. 11 percentThe variation in reported mortality rates is probably due to differences in affected populations and problems with disease surveillance, Lilith Whittles At Imperial College London.

For example, infants and children with underdeveloped immune systems may be more likely than adults to develop serious, even fatal, infections, and people with suppressed immune systems, such as those with HIV, may also be more susceptible, she says.

Additionally, some areas have little access to health care and limited surveillance for MPOX. As a result, health care providers only catch the most severe cases and miss milder cases, making the death rate appear higher than it actually is. If MPOX symptoms are increasingly misdiagnosed as other illnesses, like measles or chickenpox, more cases will go undetected, Whittles says.

In fact, most deaths from MPOX occur due to complications such as sepsis, where infection enters the bloodstream and causes organ failure, and inflammation caused by the MPOX virus that damages the lungs, he said. Piero Oriaro At Oxford University.

What are the MPOX treatment options?

In the Democratic Republic of Congo and neighboring countries where the current outbreak is occurring, there are few treatments specific to MPOX. Instead, doctors focus on treating symptoms, which usually last two to four weeks, such as reducing fever and headaches with paracetamol (acetaminophen) and cleaning skin lesions to prevent bacterial infections, he said. Jean-Claude Udahemka At the University of Rwanda.

In the UK and US, doctors can use the antiviral drug Tecovirimat to treat people with severe smallpox. Originally developed to treat smallpox, its use against the disease was based on animal studies in which it improved survival rates compared to a placebo. Tecovirimat works by binding to a protein on the surface of both variola and smallpox that the virus uses to attack. Freeing itself from infected cells spreads to other cells.

Doctors in the United States and the United Kingdom can also treat MPOX with other antiviral drugs, such as brincidofovir and cidofovir. Protecting mice from lethal doses of the mpox virus. Both brincidofivir and cidofovir Interfering with enzymes Used by viruses to replicate their genome.

Another treatment, known as VIGIV, involves injecting people with smallpox with antibodies against smallpox taken from people who have had the smallpox vaccine, thus strengthening their immune response to the virus.

How effective is mpox treatment in humans?

Animal studies suggest that these treatments may be effective against MPOX, but their effectiveness in humans is unknown. Early results from a recent randomized controlled trial (best medical evidence) in the Democratic Republic of Congo suggest that tecovirimat does not accelerate the progression of MPOX. Healing of painful lesions in children and adults infected with lineage I variants of MPOX.

Nonetheless, the researchers found that the MPOX mortality rate for participants who received the antiviral drug was 1.7 percent, an improvement over the 3.6 percent mortality rate typically seen in the Democratic Republic of Congo. But this can be partly explained by the fact that participants in the trial received close care in hospital, Oriaro says.

Ultimately, better treatments and a better understanding of MPOX's lethality will be essential to protect people, especially in the Democratic Republic of Congo, from the ongoing epidemic. Lucille Blumberg She is a researcher at the University of Pretoria in South Africa. “There's a lot of work to be done,” she says.